Novartis case sets “precedent”, says FAS
Russia’s Federal Antimonopoly Service has accused Novartis of abusing its dominant position after the Swiss drugmaker hiked the price of a cancer drug by 35%.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.